Brought to you by 
Nordion divests its Targeted Therapies business to BTG for $200mm
14 Sep 2020
Executive Summary
BTG PLC (specialized therapies for cancer, critical care, and other diseases) has paid $200mm--$185mm net of taxes and costs--to purchase the Targeted Therapies business of Nordion Inc. (medical isotopes, targeted radioactive therapies, and sterilization products). Nordion is divesting the unit so that it can focus more thoroughly on its medical isotope processing, packaging, and delivery business.
Deal Industry
- Medical Devices
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nordion divests its Targeted Therapies business to BTG for $200mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice